Response Genetics Inc (RGDXQ) financial statements (2020 and earlier)

Company profile

Business Address 1640 MARENGO ST.,
LOS ANGELES,, CA 90033
State of Incorp.
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments289
Cash and cash equivalents289
Receivables865
Prepaid expense and other current assets1
Other undisclosed current assets11 
Total current assets:111515
Noncurrent Assets
Property, plant and equipment121
Intangible assets, net (including goodwill)111
Intangible assets, net (excluding goodwill)111
Other noncurrent assets0 
Total noncurrent assets:232
TOTAL ASSETS:131817
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities443
Accounts payable221
Accrued liabilities110
Employee-related liabilities221
Interest and dividends payable0  
Debt001
Deferred revenue and credits  0
Other undisclosed current liabilities111
Total current liabilities:565
Noncurrent Liabilities
Long-term debt and lease obligation1010
Long-term debt, excluding current maturities91 
Capital lease obligations000
Total noncurrent liabilities:1010
Total liabilities:1575
Temporary equity, carrying amount 612
Stockholders' equity
Stockholders' equity attributable to parent, including:(1)6(1)
Common stock000
Additional paid in capital787157
Accumulated other comprehensive loss(0)(0)(0)
Accumulated deficit(79)(65)(57)
Warrants and rights outstanding1  
Other undisclosed stockholders' equity attributable to parent(1)  
Total stockholders' equity:(1)6(1)
TOTAL LIABILITIES AND EQUITY:131817

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
172019
Cost of revenue(0)(10)(10)
Cost of goods and services sold(10)(10) 
Other undisclosed gross profit(10)  
Gross profit:798
Operating expenses(20)(17)(18)
Other undisclosed operating income  2
Operating loss:(13)(8)(8)
Nonoperating income (expense)(0)0(0)
Other nonoperating expense  (0)
Interest and debt expense(1)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(14)(8)(8)
Other undisclosed income from continuing operations before income taxes 0 
Net loss available to common stockholders, diluted:(14)(8)(8)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net loss:(14)(8)(8)
Comprehensive loss:(14)(8)(8)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)0
Comprehensive loss, net of tax, attributable to parent:(14)(8)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: